Filed in archive
Corporate and Industrial News
by ruth on August 30, 2005
... second-quarter European biotech IPO volume was the strongest it's been since 2000. All told, in the first half of 2005, European IPO proceeds actually topped those in the US, reaching nearly $500 million, debunking yet another myth about relative exit opportunities across the Atlantic. In fact, the average value of biotech IPOs in Europe is rising. This year the average proceeds hit $40 million, more than twice what they were just two years ago. By comparison, biotech proceeds in the US have remained level at around $60 million.
Read the full article here.
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/8828
Mr Wong
Vote for Exit Opportunities for Biotech Investors: US vs Europe:
|
Rating: 8.00 out of 1 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS | See all blog subscribe options |
|
What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |







